1. Home
  2. BOC vs CCCC Comparison

BOC vs CCCC Comparison

Compare BOC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$14.06

Market Cap

435.7M

Sector

N/A

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$4.20

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
CCCC
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
435.7M
404.7M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
BOC
CCCC
Price
$14.06
$4.20
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$12.20
AVG Volume (30 Days)
97.8K
2.3M
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
$114,376,348.00
$35,947,000.00
Revenue This Year
$5.79
N/A
Revenue Next Year
$4.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.64
1.02
52 Week Low
$10.52
$1.69
52 Week High
$15.22
$5.17

Technical Indicators

Market Signals
Indicator
BOC
CCCC
Relative Strength Index (RSI) 50.59 58.78
Support Level $13.95 $3.40
Resistance Level $14.71 $4.60
Average True Range (ATR) 0.41 0.23
MACD -0.03 0.03
Stochastic Oscillator 65.68 74.21

Price Performance

Historical Comparison
BOC
CCCC

About BOC Boston Omaha Corporation

Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Share on Social Networks: